Pulse BiosciencesPLSE +3.27%31 Receivables Turnover is 1.86 as of Mar. 2026. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Pulse Biosciences ranks worse than 58.5% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pulse Biosciences's Revenue for the
three
months ended in Mar. 2026 was $0.40 Mil. Pulse Biosciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.22 Mil.
Hence, Pulse Biosciences's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.86.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Pulse Biosciences Receivables Turnover Related Terms
Pulse Biosciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Pulse Biosciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLSE vs LMAT, XRAY, KMTS: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (PLSE) has a Receivables Turnover of 1.86 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pulse Biosciences and its competitors. According to the industry distribution chart, Pulse Biosciences ranks #475 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 58.5%.
Is Pulse Biosciences' Receivables Turnover too high?
Pulse Biosciences' current Receivables Turnover is 1.86. The Medical Devices & Instruments industry median Receivables Turnover is 5.53. Pulse Biosciences' value of 1.86 is 66.4% below this industry median. Based on the distribution chart, Pulse Biosciences ranks #475 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' Receivables Turnover compare to LMAT and XRAY?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #475 out of 812 companies for Receivables Turnover. This places Pulse Biosciences in the lower half of its industry. The industry median Receivables Turnover is 5.53. Pulse Biosciences' value of 1.86 is 66.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.53, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulse Biosciences's current Receivables Turnover of 1.86 is 66.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pulse Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulse Biosciences's current Receivables Turnover is 1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current Receivables Turnover of 1.86. The current Receivables Turnover is 1.86 and 66.4% below the Medical Devices & Instruments industry median of 5.53. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current Receivables Turnover is 1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score
Get the complete analysis for PLSE
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 
